Pictor Holdings Inc has announced that its ViraScreen-Core multiplex antibody assay, a targeted proteomics test capable of detecting multiple viral antibodies from a single sample, is positioned to support evolving Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations that emphasise post-vaccination testing for hepatitis B immunity. The announcement comes amid growing emphasis on more rigorous hepatitis B immunity assessment, moving beyond assumptions based on vaccination history.

This positioning reflects a broader shift underway in how laboratories and public health systems approach hepatitis B virus (HBV) surveillance. Until recently, immunity assessment has often been secondary to infection detection, and testing protocols have been fragmented across different analytes. By bringing forward a multiplex format that integrates hepatitis B, HIV-1, HIV-2, and hepatitis C antibody detection into a single platform, Pictor aims to streamline workflows while aligning with new public health objectives.

What this shift in testing expectations reveals about current immunity gaps

The CDC’s latest focus on post-vaccination testing highlights a longstanding diagnostic blind spot. For decades, hepatitis B vaccination campaigns have operated under the assumption of long-term immunity, particularly in populations vaccinated during infancy or early childhood. However, there is now increasing evidence that antibody levels wane in a significant subset of individuals, particularly those with comorbidities or immunosuppression. Clinicians and public health practitioners are being encouraged to confirm protective antibody titers in vulnerable groups, including healthcare workers, dialysis patients, and immunocompromised individuals.

Multiplex antibody assays such as ViraScreen-Core offer an operational advantage in this evolving context. The ability to measure hepatitis B surface antibodies (anti-HBs) alongside other serologic markers from a single saliva or serum sample could reduce turnaround times and costs. For laboratories seeking to adapt quickly without overhauling existing workflows, this modular and sample-efficient design could prove appealing.

Why saliva-based testing matters in decentralized and pediatric care

One of the most clinically relevant aspects of Pictor’s assay is its validated compatibility with both serum and saliva. The company’s paired matrix studies reportedly show high concordance between sample types, which could have significant downstream effects for accessibility and compliance. In pediatric care, community health clinics, and decentralized environments where venipuncture is logistically difficult or culturally sensitive, saliva sampling expands where and how testing can be delivered.

This flexibility also aligns with broader infectious disease surveillance strategies, where population-scale screening may be limited by infrastructure and personnel. Saliva collection opens up avenues for school-based programs, mobile units, and telemedicine-enabled diagnostics—potentially advancing screening equity in underserved or geographically isolated areas.

How multiplexed infectious disease panels could alter lab economics

Although the ViraScreen-Core platform is being spotlighted in the hepatitis B context, its multiplex capability positions it as a broader infectious disease diagnostic tool. The inclusion of HIV-1, HIV-2, and hepatitis C antibodies in the same assay creates the potential for bundled screening protocols that meet multiple clinical and public health objectives with a single sample draw.

That said, the road to widespread adoption is not without hurdles. While operationally attractive, multiplex panels often raise questions around coding, reimbursement, and analytical validation. Payers may be reluctant to cover a bundled test if it is not clinically indicated for all included pathogens in every patient scenario. Laboratories, too, may face regulatory and logistical complexities in validating multi-analyte panels, particularly for saliva-based workflows.

Despite these challenges, diagnostics industry observers believe that the ongoing cost pressures on clinical labs and the increasing complexity of testing guidelines could drive a re-evaluation of multiplex formats. ViraScreen-Core’s early deployment in CLIA-certified labs suggests that it has cleared a key operational bar, but broader trust and uptake will depend on performance data from more diverse lab environments and real-world patient cohorts.

What regulatory and commercial factors could influence uptake

While the CDC’s ACIP recommendations provide an important signal to the market, they do not automatically confer regulatory clearance or payer recognition for specific assays. Clinical laboratories are still responsible for their own validation under the Clinical Laboratory Improvement Amendments (CLIA) framework. Pictor’s traction in early-adopter labs may position it well for near-term commercial momentum, but without widespread CLIA validation or Food and Drug Administration (FDA) clearance, broader scaling may remain incremental.

Furthermore, Pictor’s efforts to raise capital to support commercialization and expand its assay menu point to the financial and operational realities of entering a fragmented diagnostics market. The company’s ability to forge partnerships with large lab networks, reference testing providers, and health systems will be a major determinant of whether ViraScreen-Core becomes a mainstream option or remains a specialty tool within a niche segment.

What clinicians and regulators will be watching next

For clinical stakeholders, the question will be whether tools like ViraScreen-Core actually improve diagnostic decision-making and patient management. Serologic testing for hepatitis B is not only about identifying prior exposure or immunity—it also informs decisions around revaccination, isolation protocols, and treatment eligibility. Multiplex assays must therefore provide data that is both timely and actionable.

From a regulatory standpoint, clarity will be needed on how multiplex saliva assays will be reviewed and categorized, especially in contexts where other platforms may not yet support comparable sample types. There will also be scrutiny around how result interpretation is standardised, particularly when simultaneous antibody positivity across multiple targets requires nuanced clinical judgement.

Public health agencies, meanwhile, may see multiplex tools as a way to achieve more with fewer resources. However, operational scale-up depends on supply chain resilience, instrument availability, training support, and ongoing quality assurance. These infrastructure considerations are especially salient in lower-resource settings, where the burden of HBV and co-infections remains highest.

Why the announcement marks more than a product update

This is not simply another test entering the market—it reflects a broader inflection point in diagnostics, where targeted proteomics is beginning to demonstrate clinical relevance at scale. Unlike genomic sequencing, which often requires heavy bioinformatics support and high-cost infrastructure, proteomics assays such as those on Pictor’s PictArray platform promise faster turnaround and lower capital intensity.

The announcement also arrives at a time when many public health bodies are revisiting long-standing assumptions around immunity, surveillance, and care access. If Pictor can demonstrate that ViraScreen-Core not only meets the analytical needs of today’s labs but also enables more equitable and operationally viable testing strategies, it may serve as a blueprint for next-generation diagnostics in infectious disease management.

  ACIP, CDC, clinical diagnostics, hepatitis B, infectious disease testing, Pictor Holdings Inc, targeted proteomics, ViraScreen-Core